Повышение эффективности статистического подхода к обработке данных контроля технологического процесса транспорта нефти

Тема научной работы выбрана согласно стратегии совместного сотрудничества РФ и КНР, в которой возрастают требования к эффективности использования нефтетранспортных предприятий. Целью данной дипломной работы является изучение котроля техгологического процесса во времени на примере транспорта жидкости, при помощи метода контрольных карт Шухарта, метод главных компонент и стандарт статистика. В данной работе был произведен расчет и рассмотрена возможность осуществления технологического контроля при мониторинге многопараметрового процесса транспорта жидкости по трубопроводу.The theme of the scientific work is selected according to the strategy of joint cooperation between the Russian Federation and the PRC, in which the requirements to the effectiveness of the use of oil transportation enterprises are increasing. The purpose of this thesis is to study the control of the technological process in time using the example of fluid transport, using the method of Shewhart control charts, the method of main components and the standard statistic. In this paper, a calculation was made and the possibility of implementing technological control in monitoring a multi-parameter fluid transport process through a pipeline was considered

Intersecting Solitons, Amoeba and Tropical Geometry

We study generic intersection (or web) of vortices with instantons inside, which is a 1/4 BPS state in the Higgs phase of five-dimensional N=1 supersymmetric U(Nc) gauge theory on R_t \times (C^\ast)^2 \simeq R^{2,1} \times T^2 with Nf=Nc Higgs scalars in the fundamental representation. In the case of the Abelian-Higgs model (Nf=Nc=1), the intersecting vortex sheets can be beautifully understood in a mathematical framework of amoeba and tropical geometry, and we propose a dictionary relating solitons and gauge theory to amoeba and tropical geometry. A projective shape of vortex sheets is described by the amoeba. Vortex charge density is uniformly distributed among vortex sheets, and negative contribution to instanton charge density is understood as the complex Monge-Ampere measure with respect to a plurisubharmonic function on (C^\ast)^2. The Wilson loops in T^2 are related with derivatives of the Ronkin function. The general form of the Kahler potential and the asymptotic metric of the moduli space of a vortex loop are obtained as a by-product. Our discussion works generally in non-Abelian gauge theories, which suggests a non-Abelian generalization of the amoeba and tropical geometry.Comment: 39 pages, 11 figure

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

Background. We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. Methods. Healthy postmenopausal osteoporotic women (N = 7,492; mean age, 66.4 years) were randomized to daily doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. Safety and tolerability were assessed by adverse event (AE) reporting and routine physical, gynecologic, and breast examination. Results. Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs in the bazedoxifene groups was not different from that seen in the placebo group. The incidence of hot flushes and leg cramps was higher with bazedoxifene or raloxifene compared with placebo. The rates of cardiac disorders and cerebrovascular events were low and evenly distributed among groups. Venous thromboembolic events, primarily deep vein thromboses, were more frequently reported in the active treatment groups compared with the placebo group; rates were similar with bazedoxifene and raloxifene. Bazedoxifene showed a neutral effect on the breast and an excellent endometrial safety profile. The incidence of fibrocystic breast disease was lower with bazedoxifene 20 and 40 mg versus raloxifene or placebo. Reductions in total and low-density lipoprotein levels and increases in high-density lipoprotein levels were seen with bazedoxifene versus placebo; similar results were seen with raloxifene. Triglyceride levels were similar among groups. Conclusion. Bazedoxifene showed a favorable safety and tolerability profile in women with postmenopausal osteoporosis. © 2010 Christiansen et al; licensee BioMed Central Ltd.link_to_subscribed_fulltex

Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial

Summary: Findings from this 5-year phase 3 study of postmenopausal women with osteoporosis showed that bazedoxifene was associated with an overall favorable safety and tolerability profile, with no evidence of endometrial or breast stimulation. Overall, the results at 5 years were consistent with those seen at 3 years. Introduction: We report safety and tolerability findings from a 5-year randomized, double-blind, phase 3 study of bazedoxifene in postmenopausal women with osteoporosis. Methods: In the core study, healthy postmenopausal women with osteoporosis (N=7,492; mean age, 66.4 years) were randomized to daily doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. During the 2-year study extension, the raloxifene 60-mg treatment arm was discontinued after the 3-year database was finalized, and subjects receiving bazedoxifene 40 mg were transitioned in a blinded manner to bazedoxifene 20 mg (bazedoxifene 40-/20-mg group) after 4 years. Safety and tolerability data are reported for subjects in the bazedoxifene 20- and 40-/20-mg and placebo groups; efficacy findings are reported elsewhere. Results: A total of 3,146 subjects in the bazedoxifene 20- and 40-mg and placebo groups were enrolled in the extension study (years 4 and 5). Overall, the 5-year incidence of adverse events (AEs), serious AEs, and discontinuations due to AEs were similar among groups. The incidence of hot flushes and leg cramps was higher with bazedoxifene compared with placebo. Venous thromboembolic events, primarily deep vein thrombosis, were more frequently reported in the bazedoxifene groups compared with the placebo group. Reports of cardiac disorders and cerebrovascular events were few and evenly distributed among groups. Bazedoxifene showed a neutral effect on the breast and endometrium. Conclusion: Bazedoxifene was associated with an overall favorable safety and tolerability profile in postmenopausal women with osteoporosis over 5 years of therapy, consistent with findings at 3 years. © 2010 International Osteoporosis Foundation and National Osteoporosis Foundation